SYS-CON MEDIA Authors: Kevin Benedict, Gilad Parann-Nissany

News Feed Item

Prima BioMed to Present at 2014 WAGO Annual Meeting

SYDNEY, AUSTRALIA -- (Marketwired) -- 06/19/14 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima", "the Company") today advised that the Western Association of Gynecologic Oncologists (WAGO) Program Committee has accepted the abstract entitled "Treatment with Mucin 1-Autologous Dendritic Cell Therapy Significantly Improves Progression-Free Survival in Ovarian Cancer Patients in Second Remission" for oral presentation at the Ovarian Cancer Session at the 2014 WAGO Annual Meeting to be held from June 25-28, 2014 in California.

Dr. Heidi Gray, lead investigator, will deliver a presentation on final progression free survival (PFS) and interim overall survival (OS) data for Epithelial Ovarian Cancer patients in First or Second Remission (the CAN-003 protocol). As outlined in her presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and as previously announced, Dr Gray will highlight the positive trends demonstrated in PFS and OS for CVac in the second remission patient population.

The following are specific details regarding Prima's presentation.
Event: 2014 WAGO Annual Meeting
Date: Thursday, June 26, 2014
Time: 10:35am - 10:45am
Location: Ritz Carlton Lake Tahoe, Salon III

About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au

For further information please contact:

USA Investor/Media:
Adam Holdsworth
ProActive Capital
+1 (646) 862 4607
Email Contact

Australia Investor/Media:
Mr Matthew Gregorowski
Citadel Communications
+61 (0) 422 534 755
Email Contact

Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.